Elicio Therapeutics, Inc. (ELTX)
3.05
+0.07
(+2.35%)
USD |
NASDAQ |
Aug 25, 12:10
Elicio Therapeutics Debt to Equity Ratio : 1.782 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.782 |
| March 31, 2026 | -9.979 |
| December 31, 2025 | 8.870 |
| September 30, 2025 | 3.946 |
| June 30, 2025 | 8.125 |
| March 31, 2025 | 0.6504 |
| December 31, 2024 | -2.302 |
| September 30, 2024 | -1.372 |
| June 30, 2024 | -3.886 |
| March 31, 2024 | 1.37 |
| December 31, 2023 | 0.6082 |
| September 30, 2023 | 0.5384 |
| June 30, 2023 | 0.3143 |
| March 31, 2023 | 0.0075 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.8391 |
| September 30, 2022 | 0.0788 |
| June 30, 2022 | |
| March 31, 2022 | 0.066 |
| December 31, 2021 | 0.0572 |
| September 30, 2021 | 0.0709 |
| June 30, 2021 | 0.0619 |
| March 31, 2021 | 0.063 |
| December 31, 2020 | -0.9402 |
| September 30, 2020 | -1.10 |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -0.5799 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Precigen, Inc. | 2.257 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 31.33M |
| Total Liabilities (Quarterly) | 23.39M |
| Shareholders Equity (Quarterly) | 7.937M |
| Current Ratio | 2.770 |
| Net Debt Paydown Yield | -1.95% |